Synklino ApS

https://www.synklino.com

LinkedIn: https://www.linkedin.com/company/synklino

Synklino is a Danish biotech company developing groundbreaking therapies against cytomegalovirus (CMV), a devastating virus infection. It is a spin-out from the University of Copenhagen and the Technical University of Denmark and previously incubated at the BioInnovation Institute. The company is backed by renowned Nordic funds Eir Ventures and Vaekstfonden. Synklino’s first-in-class drug candidate SYN002 specifically targets CMV infection in transplantation and aims to change the current antiviral treatment paradigm by providing radically different therapeutic opportunities and a path for transplant recipients to live a full life again. *

	Start	2017-07-07 established (s-off)
	Predecessor	University of Copenhagen
	Industry	BIOTECH
	Industry 2	virostatic agent
	Person	Kledal, Thomas (Synklino 202110 CEO + Co-Founder)
	Person 2	Haurum, John (F-Star 201205–201810 CEO before ImClone System + Symphogen LEFT 10/18)

	Region	København (Copenhagen)
	Country	Denmark
	Street	13 Raadhusvej
	City	2920 Charlottenlund
	Tel	+45-2012-1656
		Address record changed: 2021-10-07

Basic data	Employees	n. a.

		* Document for »About Section«: Synklino ApS. (10/5/21). "Press Release: Synklino Strengthens Board of Directors and Initiates Finance Round". Copenhagen.

		Record changed: 2024-02-12

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for Synklino ApS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)